AUTOLUS THERAPEUTICS PLC Stock Price, News & Analysis

Autolus Therapeutics (Nasdaq: AUTL) announced changes to its Board of Directors effective February 2023. John H Johnson, the non-executive Chairman since September 2021, will not seek re-election to focus on his CEO role at Reaction Biology. Dr. Jay T Backstrom will also step down from the board after serving since August 2020 to concentrate on his position as CEO of Scholar Rock. Both directors contributed during a critical transition period for Autolus, including the successful pivotal FELIX trial for the lead product candidate, obe-cel. The company is now preparing for regulatory approval and commercialization.

Autolus Therapeutics plc (Nasdaq: AUTL) announced a non-exclusive license agreement with Cabaletta Bio, Inc (Nasdaq: CABA) to use Autolus' proprietary RQR8 safety switch in a cell therapy program for autoimmune diseases. This deal includes an upfront payment, potential development milestones, and royalties on sales from products using this technology. Autolus aims to enhance patient outcomes while minimizing treatment risks, highlighting its ability to monetize its technologies and advance its pipeline, complementing previous agreements with Bristol Myers Squibb and Moderna.

Autolus Therapeutics (Nasdaq: AUTL) announced on December 21, 2022, that underwriters have exercised a partial option to buy an additional 6,927,102 American Depositary Shares (ADSs) at $2.00 each. This move will yield roughly $13.9 million in gross proceeds, bringing the total raised from the public offering to approximately $163.9 million. The offering, which closed on December 13, 2022, involved a total of 81,927,102 ADSs sold. Jefferies LLC, William Blair & Company, and Wells Fargo Securities acted as joint bookrunners for the offering.

Autolus Therapeutics (Nasdaq: AUTL) presented promising updates on its clinical trials at the ASH Annual Meeting. In the ALLCAR19 trial, 35% of adult relapsed/refractory B-ALL patients achieved sustained complete remission after three years without additional therapy. The AUTO1/22 trial showed an 83% MRD negative complete response rate in challenging pediatric B-ALL cases, with no antigen-negative relapses. Additionally, AUTO4 demonstrated sustained metabolic complete remissions in peripheral T-cell lymphoma patients. Full data from the pivotal FELIX trial is expected in mid-2023.

Autolus Therapeutics plc (Nasdaq: AUTL) announced the pricing of a public offering of 75 million American Depositary Shares (ADSs) at $2.00 each, totaling $150 million in gross proceeds. The offering, set to close on December 13, 2022, includes a 30-day option for underwriters to purchase an additional 11.25 million ADSs. The proceeds will support the development of its next-generation T cell therapies targeting cancer treatment. Jefferies LLC, William Blair, and Wells Fargo Securities are the joint bookrunners for this offering.

Autolus Therapeutics plc (Nasdaq: AUTL) has initiated an underwritten public offering of American Depositary Shares (ADSs), with each ADS representing one ordinary share. The company plans to grant underwriters a 30-day option to purchase up to 15% of the ADSs sold at the public offering price. The offering is subject to market conditions and no assurance can be given regarding its completion or terms. Jefferies LLC, William Blair & Company, and Wells Fargo Securities are the joint bookrunners. The securities are offered under an effective shelf registration statement with the SEC.

Autolus Therapeutics (AUTL) has secured two milestone payments of $35 million each from Blackstone Life Sciences, totaling $70 million, due to positive interim results from the pivotal FELIX Phase 2 trial of their CAR T cell therapy, obecabtagene autoleucel (obe-cel). The first payment was received earlier than expected due to the trial meeting its primary endpoint. The second payment follows the successful demonstration of the manufacturing process for obe-cel. Autolus aims to submit a Biologics License Application to the FDA by the end of 2023.

Autolus Therapeutics plc (AUTL) announced positive interim results from its Phase 2 FELIX trial for obe-cel in relapsed/refractory adult Acute Lymphoblastic Leukemia (ALL). The study showed a promising Overall Remission Rate (ORR) of 70% among 50 evaluated patients. Safety data indicated low rates of serious adverse events, with 3% experiencing Grade 3 Cytokine Release Syndrome (CRS) and 8% experiencing Grade 3 Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS). Additionally, a $35 million milestone payment from Blackstone Life Sciences was triggered.

Autolus Therapeutics (Nasdaq: AUTL) announced the completion of the first clean room at its new commercial manufacturing facility named ‘The Nucleus’ in Stevenage, UK. This milestone is part of a broader £120 million redevelopment project aimed at creating a life sciences district, housing a cluster of cell and gene therapy companies. The facility is expected to enhance Autolus' capacity for next-generation T cell therapies. Collaboration among Autolus, Reef Group, and Merit facilitated timely project delivery despite challenges posed by the pandemic and supply chain issues.